Jan 7, 2025 · Paxus Injection, in combination with cisplatin, is used for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paxus Injection is used for the second-line treatment of AIDS-related Kaposi's sarcoma.

Food and Drug Administration

First-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) Dosage and Administration: Breast Cancer The recommend regimen for Paxus PM is 300 mg/m2 administered by intravenous infusion over 3 hours every 3 weeks.

Paxus PM Injection Concentrate is a sterile solution containing 6 mg/mL Paxus PM, 2 mg/mL Anhydrous Citric Acid BP, 527 mg/mL PEG 35 Castor Oil and Ethanol BP. Paxus PM is extremely hydrophobic, and is therefore formulated in PEG 35 castor oil and ethanol.

Jun 1, 2019 · Paclitaxel Injection USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel injection is indicated in combination with ...

As first line therapy PAXUS is. indicated in combination with cisplatin. • For the treatment of breast cancer after failure of combination. chemotherapy for metastatic disease or relapse within 6 months. of adjuvant chemotherapy. Prior therapy should …

Mar 17, 2022 · Documents history Paxus 30 6 mg/mL (30 mg/5 mL) Solution for Injection (IV Infusion)

Advanced non-small cell lung carcinoma: Paxus, in combination with cisplatin, is indicated for the treatment of non-small cell lung carcinoma (NSCLC) in patients who are not candidates for …

Jan 7, 2025 · Paxus 30mg Injection, in combination with cisplatin, is used for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.

Administration: Paxus for injection must be diluted prior to infusion. Paxus should be diluted in 0.9% sodium chloride injection, 5% dextrose injection, 5% dextrose and 0.9% sodium chloride injection, or 5% dextrose in ringer's injection to a final concentration of 0.3-1.2 mg/mL.